• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings

$2.67 As of 08/30/2021 01:00 AM ET

▼ -0.08 (-2.91%)

This chart shows the closing price for EARS by one month, three months, or twelve months.

Skip Closing Price Chart

1 month | 3 months | 12 months

Get New Auris Medical Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for EARS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EARS

Analyst Price Target is $0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for Auris Medical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.67.

This chart shows the closing price for EARS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing

From Investing Trends

The White House is scared of our countrys lithium supply running out. Thats why Biden issued executive order 14017 to figure out how to expand our lithium production. And this is GREAT news for one company whos gobbling up land in the lithium-rich Nevada desert.

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Auris Medical. This rating has held steady since December 2019, when it changed from a Buy consensus rating.


News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

Auris

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Read More

Average Volume

3,096,183 shs

Market Capitalization

$30.48 million

Frequently Asked Questions

What sell-side analysts currently cover shares of Auris Medical?

The following Wall Street analysts have issued research reports on Auris Medical in the last twelve months: Zacks Investment Research.
View the latest analyst ratings for EARS.

What is the current price target for Auris Medical?

0 Wall Street analysts have set twelve-month price targets for Auris Medical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Auris Medical in the next year.
View the latest price targets for EARS.

What is the current consensus analyst rating for Auris Medical?

Auris Medical currently has from Wall Street analysts. The stock has a consensus analyst rating of N/A.
View the latest ratings for EARS.

What other companies compete with Auris Medical?

How do I contact Auris Medicals investor relations team?

Auris Medicals physical mailing address is Clarendon House 2 Church Street, Hamilton D0, HM 11. The biotechnology companys listed phone number is (441) 295-5950 and its investor relations email address is [email protected] The official website for Auris Medical is www.aurismedical.com.

Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing

From Investing Trends

The White House is scared of our countrys lithium supply running out. Thats why Biden issued executive order 14017 to figure out how to expand our lithium production. And this is GREAT news for one company whos gobbling up land in the lithium-rich Nevada desert.

© American Consumer News, LLC dba PriceTargets.com ® 2010-2021. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103. PriceTargets.com provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target changes. PriceTargets.com keeps track of all major brokerages’ stock ratings and recommendations, including Goldman Sachs, JPMorgan Chase, Wells Fargo, Bank of America/Merrill Lynch, Citigroup, Morgan Stanley and many more. PriceTargets.com does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Do Not Sell My Information


© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided as-is and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.

Say hello

Find us at the office

Chappa- Adamitis street no. 38, 81811 Tripoli, Libya

Give us a ring

Alda Runion
+69 213 130 910
Mon - Fri, 10:00-22:00

Say hello